ReviewNature reviews. Clinical oncology2019
The changing therapeutic landscape of head and neck cancer.
Review in Nature reviews. Clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 458 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
458 citing papers in PubMed, 2 syntheses or guidelines pooled it, 794 citations in OpenAlex.
- Incidence and Risks of Chronic Rhinosinusitis in Head and Neck Cancer: A Meta-Analysis.The Laryngoscope · 2026Pooled it
- Prognostic and clinicopathological value of the controlling nutritional status (CONUT) score in patients with head and neck cancer: a meta-analysis.World journal of surgical oncology · 2024Pooled it
- Trial
- Assessment methods of pathological complete response in neoadjuvant head and neck cancer clinical trials: a scoping review.The journal of pathology. Clinical research · 2026Article
- Tumor microenvironment-simulated organoids for personalized therapy prediction in head and neck squamous cell carcinoma.Oncogene · 2026Article
- Cigarette Smoke Exposure Attenuates T2R-Mediated Apoptosis in Head and Neck Squamous Cell Carcinoma.Head & neck · 2026Article
- Article
- Aquaporin-1 gene therapy as a novel method to treat radiation-induced salivary gland damage: The case for adeno-associated virus vectors.Oral oncology · 2026Review
- DNA Repair, Epigenetic Dysregulation, and Cytokine Network Crosstalk in Head and Neck Cancer: Emerging Therapeutic Opportunities and Clinical Trials.Current oncology reports · 2026Review
- TRAPPC4 Promotes GPX4 Stability to Drive Ferroptosis Resistance and Tumor Progression in Head and Neck Squamous Cell Carcinoma.Cancer research · 2026Article
- Prospective evaluation of dose rate effects on acute radiation toxicities and quality of life in head and neck cancer.Journal of the Egyptian National Cancer Institute · 2026Article
- Reciprocal signaling-metabolic crosstalk between fibroblasts and tumor cells drives cetuximab tolerance in head and neck cancers.Journal of experimental & clinical cancer research : CR · 2026Article
- PER2 reprograms intracellular cholesterol synthesis to inhibit oral squamous cell carcinoma and the chronotherapeutic efficacy of simvastatin.Cell death discovery · 2026Article
- Tumor microenvironment responsive copper-doped carbon dots for synergistic chemotherapy and cuproptosis in laryngeal cancer.iScience · 2026Article
- SPP1 promotes lymph node metastasis and malignant progression of head and neck squamous cell carcinoma by activating FAK-AKT signaling pathway.World journal of surgical oncology · 2026Article
- Skeletal muscle status and malnutrition as predictors of short-term radiotherapy response and oral mucositis in head and neck cancer.Precision radiation oncology · 2026Article
- Artificial intelligence in head and neck cancer rehabilitation services: current state and future perspectives.Current opinion in otolaryngology & head and neck surgery · 2026Review
- Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Article
- Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma.Journal of translational internal medicine · 2026Article
- NIR-II biomimetic nanoplatform optogenetic CD274 editing of HNSCC immunogenicity for enhanced photoimmunotherapy.Materials today. Bio · 2026Article
398 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck cancers are a heterogeneous collection of malignancies of the upper aerodigestive tract, salivary glands and thyroid. In this Review, we primarily focus on the changing therapeutic landscape of head and neck squamous cell carcinomas (HNSCCs) that can arise in the oral cavity, oropharynx, hypopharynx and larynx. We highlight developments in surgical and non-surgical therapies (mainly involving the combination of radiotherapy and chemotherapy), outlining how these treatments are being used in the current era of widespread testing for the presence of human papillomavirus infection in patients with HNSCC. Finally, we describe the clinical trials that led to the approval of the first immunotherapeutic agents for HNSCC, and discuss the development of strategies to decrease the toxicity of different treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.